Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
PRLD
#2988
Prelude Therapeutics Incorporated
2.7
6
-5.80%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
-5.80%
Monthly Change
+28.37%
6 month change
+113.95%
Year Change
+253.85%
Previous Close
2.9
3
Open
2.7
6
Bid
Ask
Low
2.7
6
High
2.7
6
Volume
3
Markets
US Stock Market
Healthcare
PRLD
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
32.6 M
36.2 M
36.5 M
42.06 M
42.3 M
173.4 M
Valuation ratios
Enterprise value
3.11 B
561.19 M
209.92 M
198.24 M
57.85 M
124 M
Price to earnings ratio
—
—
-2.06
-2.01
-0.76
-2.7
Price to sales ratio
—
—
—
—
13.81
—
Price to cash flow ratio
—
—
-2.84
-2.29
-0.94
-3.15
Price to book ratio
—
—
1.22
1.04
0.74
1.26
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.25
0.37
0.52
0.44
0.72
0.87
Return on equity %
0.27
0.39
0.59
0.51
0.97
1.28
Return on invested capital %
10.89 K
8 576.16
4 233.67
2 161.61
1 600.72
—
Gross margin %
100
—
—
—
100
—
Operating margin %
534.21 K
—
—
—
1 995.91
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
517.54 K
—
—
—
1 816.76
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
19.41
15.37
9.42
10.79
5.3
17.36
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
—
—
—
0.03
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
1.77
1.77
1.36
1.32
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
—
—
7.87
7.3
1.76
4.75
Net current asset value per share
—
—
4.31
3.9
1.79
4.92
Tangible book value per share
—
—
4.13
3.93
1.73
4.86
Working capital per share
—
—
3.86
3.54
1.45
3.81
Book value per share
—
—
4.13
3.93
1.73
4.86
News
Prelude Therapeutics stock gets reiterated Market Outperform rating at Citizens
Prelude Therapeutics stock surges after FDA clears IND for cancer drug
Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)
Prelude Therapeutics stock rating reiterated at Market Outperform by Citizens
Beat the Market the Zacks Way: Goldman Sachs, Micron, Prelude in Focus
Prelude Therapeutics stock rating reiterated at Market Outperform by Citizens
Earnings call transcript: Prelude Therapeutics Q3 2025 sees stock steadiness
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.56%
Palantir, Shopify among market cap stock movers on Tuesday
Palantir, Uber among market cap stock movers on Tuesday
Prelude Therapeutics stock climbs after exclusive JAK2 option deal with Incyte
Prelude Therapeutics shifts focus to JAK2 and KAT6A programs